Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions

Lingdolinurad (ABP-671) had acceptable safety and tolerability and reduced serum uric acid (sUA) in people with hyperuricemia or gout in a new study.¹

Findings from a phase 2a study evaluating ligdolinurad were presented at the American College…